Company intelligence / Profile preview

Ridgeback Biotherapeutics

Miami, Florida, United Statesridgebackbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Ridgeback Biotherapeutics has successfully developed and commercialized two major therapeutics—EBANGA™ (ansuvimab) for Ebola and Lagevrio® (molnupiravir) for COVID‑19. EBANGA™ received FDA approval as a biologic, while Lagevrio® was granted Emergency Use Authorization in partnership with Merck. The company continues to advance additional candidates against other emerging infectious diseases.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (e.g., molnupiravir)Monoclonal antibodies (e.g., ansuvimab/mAb114)
Industry: Biotech

Drug pipeline

3 assets

ansuvimab

Approved

2 more assets in the full pipeline.

Partnerships

Merck & Co. (“Lagevrio” development/commercialization partnership)Emergent BioSolutions (“manufacturing collaboration”)

Beyond the preview

Go deeper on Ridgeback Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ridgeback Biotherapeutics.